How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?

Diagnostic Microbiology and Infectious Disease

Volumn 82, Issue 1, 2015, Pages 92-103

  Jamal, Janattul Ain ^a   Mueller, Bruce A ^b   Choi, Gordon Y S ^c   Lipman, Jeffrey ^a,d   Roberts, Jason A ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MICHIGAN   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

CRRT; CVVH; Pharmacodynamics; Pharmacokinetics; SLED

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; BETA LACTAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; ERTAPENEM; FLUCLOXACILLIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; LIPOPEPTIDE; MACROLIDE; MEROPENEM; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN; POLYSULFONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; TAZOBACTAM; TEICOPLANIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MONITORING; HEMODIALYSIS; HUMAN; HYDROPHILICITY; INOCULATION; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BINDING; RENAL REPLACEMENT THERAPY; RENAL SYSTEM PARAMETERS; SEPSIS; SEPTIC SHOCK; BACTERIAL INFECTIONS; CRITICAL ILLNESS; PROCEDURES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; DRUG MONITORING; HUMANS; RENAL REPLACEMENT THERAPY;

EID: 84928370393     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.01.013     Document Type: Article

References (120)

1. Akers K.S., Cota J.M., Frei C.R., Chung K.K., Mende K., Murray C.K. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother 2011, 55:4639-4642.
2. Allaouchiche B., Breilh D., Jaumain H., Gaillard B., Renard S., Saux M.C. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 1997, 41:2424-2427.
3. Andes D., van Ogtrop M.L., Peng J., Craig W.A. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002, 46:3484-3489.
4. Ariano R.E., Nyhlen A., Donnelly J.P., Sitar D.S., Harding G.K., Zelenitsky S.A. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005, 39:32-38.
5. Arzuaga A., Maynar J., Gascon A.R., Isla A., Corral E., Fonseca F., et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005, 45:168-176.
6. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003, 51(Suppl. 1):21-27.
7. Bauer S.R., Salem C., Connor M.J., Groszek J., Taylor M.E., Wei P., et al. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol 2012, 7:452-457.
8. Bellmann R., Falkensammer G., Seger C., Weiler S., Kountchev J., Joannidis M. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration. Int J Clin Pharmacol Ther 2010, 48:243-249.
9. Beumier M., Roberts J.A., Kabtouri H., Hites M., Cotton F., Wolff F., et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother 2013, 68:2859-2865.
10. Bilgrami I., Roberts J.A., Wallis S.C., Thomas J., Davis J., Fowler S., et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother 2010, 54:2974-2978.
11. Briasoulis A., Agarwal V., Pierce W.J. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011, 120:103-110.
12. Burkhardt O., Hafer C., Langhoff A., Kaever V., Kumar V., Welte T., et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009, 24:267-271.
13. Capellier G., Cornette C., Boillot A., Guinchard C., Jacques T., Blasco G., et al. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit Care Med 1998, 26:88-91.
14. Chaijamorn W., Jitsurong A., Wiwattanawongsa K., Wanakamanee U., Dandecha P. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents 2011, 38:152-156.
15. Chapuis T.M., Giannoni E., Majcherczyk P.A., Chiolero R., Schaller M.D., Berger M.M., et al. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14:R51.
16. Chatellier D., Jourdain M., Mangalaboyi J., Ader F., Chopin C., Derambure P., et al. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002, 28:214-217.
17. Choi G., Gomersall C.D., Lipman J., Wong A., Joynt G.M., Leung P., et al. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. Int J Antimicrob Agents 2004, 24:468-472.
18. Clark W.R., Mueller B.A., Kraus M.A., Macias W.L. Extracorporeal therapy requirements for patients with acute renal failure. J Am Soc Nephrol 1997, 8:804-812.
19. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
20. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003, 17:479-501.
21. Craig W.A., Redington J., Ebert S.C. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991, 27(Suppl. C):29-40.
22. D'Arcy D.M., Casey E., Gowing C.M., Donnelly M.B., Corrigan O.I. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol 2012, 13:14.
23. DelDot M.E., Lipman J., Tett S.E. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004, 58:259-268.
24. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637.
25. Deshpande P., Chen J., Gofran A., Murea M., Golestaneh L. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED). Nephrol Dial Transplant 2010, 25:2632-2636.
26. Drusano G.L., Preston S.L., Fowler C., Corrado M., Weisinger B., Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004, 189:1590-1597.
27. Drusano G.L., Fregeau C., Liu W., Brown D.L., Louie A. Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model. Antimicrob Agents Chemother 2010, 54:4368-4372.
28. Dulhunty J.M., Roberts J.A., Davis J.S., Webb S.A., Bellomo R., Gomersall C., et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013, 56:236-244.
29. Escobar L., Andresen M., Downey P., Gai M.N., Regueira T., Borquez T., et al. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. Int J Antimicrob Agents 2014, 44:163-167.
30. Eyler R.F., Vilay A.M., Nader A.M., Heung M., Pleva M., Sowinski K.M., et al. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. Antimicrob Agents Chemother 2014, 58:1320-1326.
31. Fealy N., Baldwin I., Bellomo R. The effect of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Crit Care Resusc 2002, 4:266-270.
32. Fiaccadori E., Maggiore U., Rotelli C., Giacosa R., Parenti E., Picetti E., et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004, 32:2437-2442.
33. Fish D.N., Teitelbaum I., Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005, 49:2421-2428.
34. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37:1073-1081.
35. Friedrich J.O., Wald R., Bagshaw S.M., Burns K.E., Adhikari N.K. Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. Crit Care 2012, 16:R146.
36. Garonzik S.M., Li J., Thamlikitkul V., Paterson D.L., Shoham S., Jacob J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294.
37. Gatward J.J., Gibbon G.J., Wrathall G., Padkin A. Renal replacement therapy for acute renal failure: a survey of practice in adult intensive care units in the United Kingdom. Anaesthesia 2008, 63:959-966.
38. Giles L.J., Jennings A.C., Thomson A.H., Creed G., Beale R.J., McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000, 28:632-637.
39. Hansen E., Bucher M., Jakob W., Lemberger P., Kees F. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Intensive Care Med 2001, 27:371-375.
40. Hashimoto S., Honda M., Yamaguchi M., Sekimoto M., Tanaka Y. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ASAIO J 1997, 43:84-88.
41. Hidaka S., Goto K., Hagiwara S., Iwasaka H., Noguchi T. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Yakugaku Zasshi 2010, 130:87-94.
42. Honore P.M., Jacobs R., Joannes-Boyau O., Lochy S., Boer W., De Waele E., et al. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif 2014, 37:291-295.
43. Hoste E.A., Lameire N.H., Vanholder R.C., Benoit D.D., Decruyenaere J.M., Colardyn F.A. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003, 14:1022-1030.
44. Isla A., Maynar J., Sanchez-Izquierdo J.A., Gascon A.R., Arzuaga A., Corral E., et al. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol 2005, 45:1294-1304.
45. Isla A., Gascon A.R., Maynar J., Arzuaga A., Sanchez-Izquierdo J.A., Pedraz J.L. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy 2007, 53:194-201.
46. Jamal J.A., Mat-Nor M.B., Mohamad-Nor F.S., Udy A.A., Wallis S.C., Lipman J., et al. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 2015, 45:41-45.
47. Joannes-Boyau O., Honore P.M., Perez P., Bagshaw S.M., Grand H., Canivet J.L., et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013, 39:1535-1546.
48. Karvanen M., Plachouras D., Friberg L.E., Paramythiotou E., Papadomichelakis E., Karaiskos I., et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2013, 57:668-671.
49. Kashuba A.D., Nafziger A.N., Drusano G.L., Bertino J.S. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999, 43:623-629.
50. Kellum J.A., Ronco C. Dialysis: Results of RENAL-what is the optimal CRRT target dose?. Nat Rev Nephrol 2010, 6:191-192.
51. Khadzhynov D., Slowinski T., Lieker I., Spies C., Puhlmann B., Konig T., et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther 2011, 49:656-665.
52. Kielstein J.T., Czock D., Schopke T., Hafer C., Bode-Boger S.M., Kuse E., et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006, 34:51-56.
53. Kielstein J.T., Burkhardt O., Bode-Boeger S.M. Dose matters: dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. Crit Care Med 2009, 37:2491-2492.
54. Kielstein J.T., Eugbers C., Bode-Boeger S.M., Martens-Lobenhoffer J., Haller H., Joukhadar C., et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis - a pharmacokinetic study. Nephrol Dial Transplant 2010, 25:1537-1541.
55. Kim W.Y., Huh J.W., Lim C.M., Koh Y., Hong S.B. A comparison of acute kidney injury classifications in patients with severe sepsis and septic shock. Am J Med Sci 2012, 344:350-356.
56. Krueger W.A., Schroeder T.H., Hutchison M., Hoffmann E., Dieterich H.J., Heininger A., et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998, 42:2421-2424.
57. Krueger W.A., Neeser G., Schuster H., Schroeder T.H., Hoffmann E., Heininger A., et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 2003, 49:280-286.
58. Lam P.K.N., Tian Q., Ip M., Gomersall C.D. In vitro adsorption of gentamicin and netilmicin by polyacrylonitrile and polyamide hemofiltration filters. Antimicrob Agents Chemother 2010, 54:963-965.
59. Langgartner J., Lehn N., Gluck T., Herzig H., Kees F. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. Chemotherapy 2007, 53:370-377.
60. Langgartner J., Vasold A., Gluck T., Reng M., Kees F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008, 34:1091-1096.
61. Legrand M., Darmon M., Joannidis M., Payen D. Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med 2013, 39:101-108.
62. Li J., Rayner C.R., Nation R.L., Deans R., Boots R., Widdecombe N., et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005, 49:4814-4815.
63. Li C., Du X., Kuti J.L., Nicolau D.P. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007, 51:1725-1730.
64. Lonnemann G., Floege J., Kliem V., Brunkhorst R., Koch K.M. Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. Nephrol Dial Transplant 2000, 15:1189-1193.
65. Lorenzen J.M., Broll M., Kaever V., Burhenne H., Hafer C., Clajus C., et al. Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol 2012, 7:385-390.
66. Macias W.L., Mueller B.A., Scarim S.K. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991, 50:688-694.
67. Malone R.S., Fish D.N., Abraham E., Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45:3148-3155.
68. Malone R.S., Fish D.N., Abraham E., Teitelbaum I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45:2949-2954.
69. Mariat C., Venet C., Jehl F., Mwewa S., Lazarevic V., Diconne E., et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care 2006, 10:R26.
70. Markou N., Fousteri M., Markantonis S.L., Zidianakis B., Hroni D., Boutzouka E., et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012, 67:2459-2462.
71. Mauro L.S., Peloquin C.A., Schmude K., Assaly R., Malhotra D. Clearance of linezolid via continuous venovenous hemodiafiltration. Am J Kidney Dis 2006, 47:e83-e86.
72. McKinnon P.S., Paladino J.A., Schentag J.J. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351.
73. Mehta R.L., Letteri J.M. Current status of renal replacement therapy for acute renal failure. A survey of US nephrologists. The National Kidney Foundation Council on Dialysis. Am J Nephrol 1999, 19:377-382.
74. Meyer B., Ahmed el Gendy S., Delle Karth G., Locker G.J., Heinz G., Jaeger W., et al. How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res 2003, 26:135-140.
75. Meyer B., Kornek G.V., Nikfardjam M., Karth G.D., Heinz G., Locker G.J., et al. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 2005, 56:172-179.
76. Moise-Broder P.A., Forrest A., Birmingham M.C., Schentag J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
77. Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
78. Mueller B.A., Scoville B.A. Adding to the armamentarium: antibiotic dosing in extended dialysis. Clin J Am Soc Nephrol 2012, 7:373-375.
79. Mueller B.A., Scarim S.K., Macias W.L. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 1993, 21:172-179.
80. Mueller S.C., Majcher-Peszynska J., Hickstein H., Francke A., Pertschy A., Schulz M., et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002, 46:1557-1560.
81. O'Reilly P., Tolwani A. Renal replacement therapy III: IHD, CRRT, SLED. Crit Care Clin 2005, 21:367-378.
82. Overberger P., Pesacreta M., Palevsky P.M. Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin J Am Soc Nephrol 2007, 2:623-630.
83. Petejova N., Zahalkova J., Duricova J., Kacirova I., Brozmanova H., Urbanek K., et al. Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. J Chemother 2012, 24:107-112.
84. Petejova N., Martinek A., Zahalkova J., Duricova J., Brozmannova H., Urbanek K., et al. Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012, 158:65-72.
85. Petejova N., Martinek A., Zahalkova J., Duricova J., Brozmanova H., Urbanek K., et al. Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012, 156:342-347.
86. Rayner C.R., Forrest A., Meagher A.K., Birmingham M.C., Schentag J.J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003, 42:1411-1423.
87. Rhomberg P.R., Fritsche T.R., Sader H.S., Jones R.N. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn Microbiol Infect Dis 2006, 56:57-62.
88. Ricci Z., Ronco C., D'Amico G., De Felice R., Rossi S., Bolgan I., et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant 2006, 21:690-696.
89. Robatel C., Decosterd L.A., Biollaz J., Eckert P., Schaller M.D., Buclin T. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol 2003, 43:1329-1340.
90. Roberts J.A., Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45:755-773.
91. Roberts J.A., Roberts M.S., Robertson T.A., Dalley A.J., Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration?. Crit Care Med 2009, 37:926-933.
92. Roberts J.A., Ulldemolins M., Roberts M.S., McWhinney B., Ungerer J., Paterson D.L., et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332-339.
93. Roberts J.A., Field J., Visser A., Whitbread R., Tallot M., Lipman J., et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 2010, 54:3635-3640.
94. Roberts J.A., Udy A.A., Bulitta J.B., Stuart J., Jarrett P., Starr T., et al. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. J Antimicrob Chemother 2014, 69:2508-2516.
95. Ronco C., Zanella M., Brendolan A., Milan M., Canato G., Zamperetti N., et al. Management of severe acute renal failure in critically ill patients: an international survey in 345 centres. Nephrol Dial Transplant 2001, 16:230-237.
96. Rybak M.J., Lomaestro B.M., Rotschafer J.C., Moellering R.C., Craig W.A., Billeter M., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
97. Safdar N., Andes D., Craig W.A. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004, 48:63-68.
98. Seyler L., Cotton F., Taccone F.S., De Backer D., Macours P., Vincent J.L., et al. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011, 15:R137.
99. Smith N.L., Freebairn R.C., Park M.A., Wallis S.C., Roberts J.A., Lipman J. Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Crit Care Resusc 2012, 14:312-315.
100. Sowinski K.M., Magner S.J., Lucksiri A., Scott M.K., Hamburger R.J., Mueller B.A. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol 2008, 3:355-361.
101. Spooner A.M., Deegan C., D'Arcy D.M., Gowing C.M., Donnelly M.B., Corrigan O.I. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. BMC Clin Pharmacol 2011, 11:11.
102. Swoboda S., Ober M.C., Lichtenstern C., Saleh S., Schwenger V., Sonntag H.G., et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010, 66:291-298.
103. Taccone F.S., de Backer D., Laterre P.F., Spapen H., Dugernier T., Delattre I., et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011, 37:531-535.
104. Tang G.J., Tang J.J., Lin B.S., Kong C.W., Lee T.Y. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand 1999, 43:726-730.
105. Tegeder I., Bremer F., Oelkers R., Schobel H., Schuttler J., Brune K., et al. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother 1997, 41:2640-2645.
106. Tegeder I., Neumann F., Bremer F., Brune K., Lotsch J., Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999, 65:50-57.
107. Thalhammer F., Schenk P., Burgmann H., El Menyawi I., Hollenstein U.M., Rosenkranz A.R., et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998, 42:2417-2420.
108. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables for interpretation of MICs and zone diameter 2014, version 4.0 [Online] Available:, [Accessed 31 August 2014]. http://www.eucast.org.
109. The RENAL study investigators Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. Crit Care Resusc 2008, 10:225-230.
110. Traunmuller F., Schenk P., Mittermeyer C., Thalhammer-Scherrer R., Ratheiser K., Thalhammer F. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002, 49:129-134.
111. Triginer C., Fernandez R., Izquierdo I., Rello J., Benito S. Gentamicin pharmacokinetic changes related to mechanical ventilation. DICP 1989, 23:923-924.
112. Uchino S., Kellum J.A., Bellomo R., Doig G.S., Morimatsu H., Morgera S., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818.
113. Ulldemolins M., Roberts J.A., Rello J., Paterson D.L., Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011, 50:99-110.
114. van der Werf T.S., Mulder P.O., Zijlstra J.G., Uges D.R., Stegeman C.A. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997, 23:873-877.
115. Ververs T.F., van Dijk A., Vinks S.A., Blankestijn P.J., Savelkoul J.F., Meulenbelt J., et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000, 28:3412-3416.
116. Vilay A.M., Grio M., Depestel D.D., Sowinski K.M., Gao L., Heung M., et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011, 39:19-25.
117. Wallis S.C., Mullany D.V., Lipman J., Rickard C.M., Daley P.J. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 2001, 27:665-672.
118. Wenisch J.M., Meyer B., Fuhrmann V., Saria K., Zuba C., Dittrich P., et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2012, 67:977-983.
119. Wolter K., Claus M., Fritschka E. Pharmacokinetics and dosage recommendations of teicoplanin in patients treated by continuous veno-venous haemodialysis (CVVHD). Eur J Clin Pharmacol 1994, 46:179-180.
120. Yagasaki K., Gando S., Matsuda N., Kameue T., Ishitani T., Hirano T., et al. Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration. Intensive Care Med 2003, 29:2094-2095.